News

Article

Pharma Pulse 7/25/24: Driving CAR-Ts for Treatment in Cancer and Immunology, CrowdStrike Explains What Went Wrong in Global Outage & more

Author(s):

Miranda Schmalfuhs

The latest news for pharma industry insiders.

Driving CAR-Ts for Treatment in Cancer and Immunology

A deep dive into why this therapy has demonstrated effectiveness in various areas, including for tumors.

Ongoing Stigma Remains a Major Obstacle in the Fight Against HIV | AIDS 2024

At the 25th annual international AIDS Conference in Munich, Germany, a group of international experts discussed the impact of HIV-related stigma and discrimination on efforts to end the HIV pandemic as a public health threat by 2030.

CrowdStrike Explains What Went Wrong Days After Global Tech Outage

Cybersecurity company lays out steps to prevent future quality-control disruptions.

Pfizer Announces Positive Topline Results From Phase III Study of Hemophilia A Gene Therapy Candidate

Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis.

Matt Braun on LinkedIn

Great insights by Abid Rahman from EVERSANA on the power of #AIas it revolutionizes operations across many industries, including #pharma. Always great to see a publication like Pharmaceutical Executive want to connect with experts.

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Gen Li
Robert Lisicki
Gen Li
Gen Li
Dr. Ben Zeskind
Gen Li
Dr. Ben Zeskind
Gen Li
Related Content
Spine BioPharma’s TGF-β Antagonist Misses Primary Endpoint in Phase III Degenerative Disc Disease Trial
August 5th 2025

Spine BioPharma’s TGF-β Antagonist Misses Primary Endpoint in Phase III Degenerative Disc Disease Trial

Don Tracy, Associate Editor
Despite missing the primary endpoint, SB-01 demonstrated durable clinical improvements and consistent results in the Phase III MODEL trial (NCT05516992), reinforcing its potential as a non-surgical treatment for chronic low back pain associated with degenerative disc disease.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 5th 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Fatal Adverse Event Leads Allogene to Discontinue Novel Monoclonal Antibody, Adjust Cema-Cel Trial Protocol for Large B-Cell Lymphoma
August 5th 2025

Fatal Adverse Event Leads Allogene to Discontinue Novel Monoclonal Antibody, Adjust Cema-Cel Trial Protocol for Large B-Cell Lymphoma

Don Tracy, Associate Editor
Following the discontinuation of ALLO-647 due to a treatment-related death, Allogene will move forward with a streamlined outpatient regimen aimed at accelerating enrollment and regulatory review in the Phase II ALPHA3 trial (NCT06500273).
Beyond the Prescription: Pharma's Role in Digital Health Conversations
August 5th 2025

Beyond the Prescription: Pharma's Role in Digital Health Conversations

Canopy
Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
GAIN Therapeutics Ramps Up for Next Big Step in Parkinson’s Drug Development
August 5th 2025

GAIN Therapeutics Ramps Up for Next Big Step in Parkinson’s Drug Development

Don Tracy, Associate Editor
Gene Mack, CEO, GAIN Therapeutics, outlines how early trial results for GT-02287 are shaping the company’s strategy for advancing a potential new treatment for Parkinson’s disease.
Peter Tummino
August 5th 2025

Computational Chemistry in Drug Discovery: Q&A with Dr. Peter Tummino

Mike Hollan
Computational chemistry combined with AI technologies has become a powerful tool for assessing small molecule properties, high-resolution protein structures, and molecular mechanism of action, as well as optimizing target selection and small molecule design.